Dipiperon 40 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

dipiperon 40 mg tabletter

eumedica pharmaceuticals gmbh - pipamperonhydrochlorid - tabletter - 40 mg

Orap 1 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orap 1 mg tabletter

eumedica pharmaceuticals gmbh - pimozid - tabletter - 1 mg

Temgesic 0,3 mg/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

temgesic 0,3 mg/ml injektionsvæske, opløsning

eumedica pharmaceuticals gmbh - buprenorphinhydrochlorid - injektionsvæske, opløsning - 0,3 mg/ml

Orap 4 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orap 4 mg tabletter

eumedica pharmaceuticals gmbh - pimozid - tabletter - 4 mg

Temgesic 0,2 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

temgesic 0,2 mg resoribletter, sublinguale

eumedica pharmaceuticals gmbh - buprenorphinhydrochlorid - resoribletter, sublinguale - 0,2 mg

Temgesic 0,4 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

temgesic 0,4 mg resoribletter, sublinguale

eumedica pharmaceuticals gmbh - buprenorphinhydrochlorid - resoribletter, sublinguale - 0,4 mg

Beromun Den Europæiske Union - dansk - EMA (European Medicines Agency)

beromun

belpharma s.a. - tasonermin - sarkom - immunostimulants, - beromun er angivet i voksne som et supplement til kirurgi for efterfølgende fjernelse af tumor, således at forhindre eller forsinke amputation, eller i det palliative situation, for irresectable blødt væv sarkom af lemmer, som bruges i kombination med melphalan via mild hyperthermic isoleret-lem perfusion (ilp).

Pepaxti Den Europæiske Union - dansk - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - multipelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.